Department of Urology, S. Pio da Pietrelcina Hospital, Vasto, Italy.
Int Braz J Urol. 2011 Jan-Feb;37(1):57-66. doi: 10.1590/s1677-55382011000100008.
Neuroendocrine differentiation is a hallmark of prostate cancer. The aim of our study was the detection of the parallel expression of neuroendocrine related markers using a prostate tissue microarray (TMA).
Our study was aimed at detecting the parallel expression of NeuroD1, Chromogranin-A (ChrA), Androgen Receptor (AR) and Ki-67 by immunohistochemistry on prostate cancer tissue microarray. The data was analyzed using SAS version 8.2 (SAS Inc, Cary, NC). The relationships between NeuroD1, ChrA and AR expressions and patients' characteristics were investigated by multivariate logistic regression analysis. Progression and Overall Survival (OS) distributions were calculated using Kaplan-Meier method.
Tissue reactivity for NeuroD1, ChrA and AR concerned 73%, 49% and 77% of the available cases, respectively. Regarding overall survival, there were 87 deaths and 295 patients alive/censored (6 years of median follow-up). Seventy-seven disease progressions occurred at the median follow-up 5.4y. A significant correlation between NeuroD1, ChrA and AR expression was observed (p < 0.001 and p < 0.03, respectively). Additionally, ChrA was strongly associated in multivariate analysis to Gleason score and Ki67 expression (p < 0.009 and p < 0.0052, respectively). Survival analysis showed no association between markers neither for overall nor for cancer-specific survival.
The results highlight that NeuroD1, Chromogranin-A and Androgen Receptor are strongly associated, however their expression does not correlate with overall survival or disease progression.
神经内分泌分化是前列腺癌的一个标志。我们的研究目的是使用前列腺组织微阵列（TMA）检测神经内分泌相关标志物的平行表达。
我们的研究旨在通过免疫组织化学检测前列腺癌组织微阵列中 NeuroD1、嗜铬粒蛋白 A（ChrA）、雄激素受体（AR）和 Ki-67 的平行表达。使用 SAS 版本 8.2（SAS Inc，Cary，NC）分析数据。通过多变量逻辑回归分析研究 NeuroD1、ChrA 和 AR 表达与患者特征之间的关系。使用 Kaplan-Meier 方法计算进展和总生存（OS）分布。
NeuroD1、ChrA 和 AR 的组织反应性分别为 73%、49%和 77%的可用病例。关于总生存，有 87 例死亡和 295 例存活/删失（中位随访 6 年）。在中位随访 5.4y 时发生了 77 例疾病进展。观察到 NeuroD1、ChrA 和 AR 表达之间存在显著相关性（p < 0.001 和 p < 0.03，分别）。此外，ChrA 在多变量分析中与 Gleason 评分和 Ki67 表达强烈相关（p < 0.009 和 p < 0.0052，分别）。生存分析显示标志物与总生存或癌症特异性生存均无关联。
结果表明，NeuroD1、嗜铬粒蛋白 A 和雄激素受体之间存在强烈相关性，但它们的表达与总生存或疾病进展无关。
